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Abstract
Introduction: Fibromyalgia (FM) is characterized by chronic pain. Impaired growth hormone responses and
reduced serum insulin-like growth factor 1 (IGF-1) are common in FM. The aim was to examine changes in serum
IGF-1, cerebrospinal fluid (CSF), neuropeptides, and cytokines during aerobic exercise in FM patients.
Methods: In total, 49 patients (median age, 52 years) with FM were included in the study. They were randomized
to either the moderate- to high-intensity Nordic Walking (NW) program (n = 26) or the supervised low-intensity
walking (LIW) program (n = 23). Patients participated in blood tests before and after 15 weeks of aerobic exercise.
Changes in serum levels of free IGF-1, pain rating on a 0- to 100-mm scale, pain threshold, and 6-minute walk test
(6MWT) were examined. CSF, neuropeptides, matrix metalloproteinase 3 (MMP-3), and inflammatory cytokines were
determined. Nonparametric tests were used for group comparisons and correlation analyses.
Results: Serum free IGF-1 levels did not change during 15 weeks of exercise between the two groups, although
the 6MWT significantly improved in the NW group (p = 0.033) when compared with LIW. Pain did not significantly
change in any of the groups, but tended to decrease (p = 0.052) over time in the total group. A tendency toward
a correlation was noted between baseline IGF-1 and a decrease of pain in response to exercise (r = 0.278; p =
0.059). When adjusted for age, this tendency disappeared. The change in serum free IGF-1 correlated positively
with an alteration in CSF substance P (SP) levels (rs = 0.495; p = 0.072), neuropeptide Y (NPY) (rs = 0.802; p = 0.001),
and pain threshold (rs = 0.276; p = 0.058). Differing CSF SP levels correlated positively to a change in pain
threshold (rs = 0.600; p = 0.023), whereas the shift in CSF MMP-3 inversely correlated with an altered pain threshold
(rs = -0.569; p = 0.034).
Conclusions: The baseline level of serum free IGF-1 did not change during high or low intensity of aerobic
exercise. Changes in IGF-1 correlated positively with a variation in CSF SP, NPY, and pain threshold. These data
indicate a beneficial role of IGF-1 during exercise in FM.
Trial registration: ClinicalTrials.govNCT00643006.
Introduction
Fibromyalgia (FM) is characterized by chronic pain, ten-
derness [1], and enhanced central sensitivity [2]. Sub-
stance P (SP) is associated with central pain sensitivity
in FM patients. Low-grade inflammation could be
involved in the pathogenesis. Despite increased central
sensitivity, long-term physical exercise appears to
improve physical capacity and pain in FM, although not
in all patients [3]. Exercise at moderate-to-high intensity
results in better improvement of physical functions than
does exercise at low intensity [4]. Some exercise studies
have reported decreased pain after exercise intervention
[3]. The biologic mechanisms controlling changes in
pain in FM requires further elucidation.
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Approximately one third of FM patients are estimated
to suffer from growth hormone (GH) deficiency, with
impaired growth hormone responses leading to reduced
insulin-like growth factor 1 (IGF-1), a critical mediator
of growth hormone [5-7]. A previous study found that
GH dysfunction was associated with increased pain
scores during an exercise test as well as with higher pre-
exercise levels of interleukin-6 (IL-6) and interleukin-8
(IL-8) [8]. Regular exercise is expected to increase the
resting level of IGF-1 in healthy individuals [9], but no
increase was found in patients with FM who exercised
for 6 months [10]. Together with insulin, IGF-1 is a
central regulator for cell growth, survival, and energy
metabolism in the body and the central nervous system
(CNS). The major IGF-binding protein in serum and
extracellular fluid is insulin-like growth binding protein
3 (IGFBP3). IGFBP3 did not change significantly in FM
patients after 6 months of exercise [10].
Nerve growth factor (NGF) is increased in cerebrospinal
fluid (CSF) in FM patients [11]. NGF supports neuronal
growth, differentiation, and modulates neuroplasticity [12].
NGF promotes sensory nerve sprouting, SP release
[13,14], and is induced by proinflammatory cytokines [15].
SP is increased in CSF of FM patients [16-18]. CSF SP
levels are stable over time in FM patients; however,
increases in SP correlates to small increases in pain [16].
Neuropeptide Y (NPY) serum levels are increased in FM
patients but not associated with clinical severity [19,20].
NPY is neuroprotective [21,22], and counteracts inflam-
matory and neuropathic pain through the endogeneous
opioid system [23,24]. NPY expression in ganglionic neu-
rons is promoted by NGF [25].
Interleukin-6 (IL-6) is a proinflammatory cytokine and
can induce short-term nociceptor hypersensitivity [26].
CSF IL-6 is increased in the complex regional pain syn-
drome [27] and radiculopathy [28], and serum IL-6 is
increased in FM [29]. Interleukin-8 (IL-8) is also proin-
flammatory, is involved in persistent [29] nociceptor
hypersensitivity, and is increased in chronic orthopedic
pain [30]. IL-8 has been shown to be elevated in CSF [31]
and in serum [29,32] in FM. Matrix metalloproteinase-3s
(MMP-3s) are changed during exercise [33]. MMP-3 and
other MMPs cooperate in remodeling of the extracellular
matrix, in inflammatory processes [34], and in neural
remodeling in the CNS [35,36].
The aim of the study was to study the effect of 15-
week moderate- to high-intensity aerobic exercise on
the level of serum bioactive IGF-1 in women with FM.
Low-intensity aerobic exercise was used by a control
group. Changes in IGF-1, IGFBP3, pain, and CNS mar-
kers of inflammation and neuropeptides were studied to
get a better insight into the biologic mechanisms
involved in pain in FM.
Materials and methods
Study design and subjects
Forty-nine patients with FM formed the study popula-
tion. Patients were randomized either to a moderate- to
high-intensity Nordic Walking (NW) program (n = 26)
or a supervised low-intensity walking (LIW) program (n
= 23). The supervised exercise programs were con-
ducted twice a week for 40 to 45 minutes for 15 weeks.
They participated in a blood test at baseline, after 15
weeks of exercise, and at 30 weeks of follow-up. The
effects of Nordic walking on body function were
reported previously [4], showing that NW resulted in
better improvement in the 6-minute walk test (6MWT)
and aerobic capacity, when compared with patients in
LIW. Pain did not significantly change in any of the
exercise groups. For patient characteristics, see Table 1.
Criteria for inclusion: Women with FM, aged 20 to 60
years, and with interest in exercising outdoors twice a
week for 15 weeks, to participate at blood test at baseline
and after the exercise period. To ensure that the patients
would manage the planned aerobic exercise, a bicycle test
at 50 watts was included in the inclusion criteria. All
included patients managed to perform the test. They were
also invited to participate in an examination of cerebrosp-
inal fluid, which, however, was not a criterion of inclusion.
FM was defined by the ACR 1990 criteria [1]: a history of
long-lasting generalized pain and pain in at least 11 of 18
tender points examined by manual palpation.
Criteria for exclusion: Patients not speaking or reading
Swedish, other severe somatic or psychiatric disease,
ongoing or planned physical therapy, including exercise,
and inability to accept times for planned exercise
sessions.
Clinical measurements
The pain threshold was examined by using an algometer
(Somedic Production AB, Sollentuna, Sweden), mea-
sured in kilopascals (kPa) [37]. The pain threshold was
measured in two tender-point locations in the upper
and lower extremities, respectively. The mean value was
applied, and a higher value indicates better health.
Table 1 Patient characteristics and pharmacologic
treatment
Patient characteristics (n = 49) Median (interquartile range)
Age, years 52 (48-56)
Symptom duration, years 11 (7-15)
Tender points, n 15 (13-16)
Pharmacologic treatment n (%)
Analgesics, yes 40 (82%)
Antidepressants/sedatives, yes 31 (63%)
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Pain was rated on a visual analog scale (0 to 100) of the
Fibromyalgia Impact Questionnaire (FIQ) [38] and reflects
subjective estimation of overall pain intensity during the
last week. A higher score indicates more-severe pain.
The 6-minute walk test (6MWT) reflects physical
restriction related to the pain disorder. The patient was
instructed to walk as quickly as possible but not to run.
The distance covered was measured in meters [39].
Blood and cerebrospinal fluid (CSF) sampling
Serum was collected at rest (n = 49) at baseline and
after 15 weeks in the exercise program and at 30 weeks
of follow-up (n = 40). Serum samples were acquired by
venipuncture of the cubital vein.
Twenty-six patients agreed to participate in an examina-
tion of cerebrospinal fluid (CSF) at baseline, and 15
patients also participated after 15 weeks of exercise. CSF
was collected through lumbar puncture through the L3/L4
interspace. Collected blood and cerebrospinal fluid sam-
ples were centrifuged at 800 g for 3 minutes, aliquoted,
and stored frozen at -70°C until use.
Laboratory analyses
Biologic markers were analyzed with enzyme-linked immu-
nosorbent assay (ELISA) by using commercially available
kits. Assays specific for IL-8 (DY208, detection limit 31 pg/
ml), MMP-3 (DY513, 1.4 pg/ml), serum free bioactive IGF-
1 (DY291, 4 pg/ml), and IGFBP3 (DY675, 0.125 ng/ml)
were purchased from R and D Systems (Minneapolis, MN,
USA). An assay specific for human IL-6 (M1916, 0.6 pg/ml)
was purchased from Sanquin Reagents (Amsterdam, The
Netherlands). Assays specific for SP (FEK-061-05, 1 pg/ml)
and NPY (FEK-049-03, 1 pg/ml) were purchased from
Phoenix Pharmaceuticals (Burlingame, CA, USA). The
human NGF-specific assay was purchased from Promega
(Madison, WI, USA; 4 pg/ml). All assays were run accord-
ing to recommendations of the manufacturers. Ordinary
colorimetric ELISA was read with a Spectramax 340 from
Molecular Devices (Sunnyvale, CA, USA), and fluorescent
ELISA assays were read with a Mithras LB940 from Bert-
hold Technologies (Bad Wildbad, Germany).
Ethics
The study was approved by the ethics committee of
Sahlgrenska University Hospital (220-09). Written and
verbal information was given to all patients, and written




Descriptive data are presented as median, interquartile
range, the number, and percentage. The Mann-
Whitney U test and Kruskal-Wallis test were used to
analyze the differences in continuous variables between
the groups. The mean of baseline and posttest values
was calculated for each individual, and these means
were used in group comparisons. The Wilcoxon
signed-rank test was used for comparisons of continu-
ous variables within groups. Relations between the
variables were examined with the Spearman correlation
coefficient. Partial correlational analyses were per-
formed to adjust for baseline pain and age. To control
for possible Type I errors, the upper limit of number
of false significances was calculated by the following
formula: (number of tests - number of significant tests
on the level of a) × a/(1-a). All significant tests were
two-tailed, and values of p < 0.05 were considered sig-
nificant. All statistical evaluation of data was done by
using the statistic program SPSS Statistics v. 19.
Results
Clinical effects of exercise
Baseline values for 6MWT, pain, and pain threshold
are presented in Table 2. The 6MWT was found signif-
icantly to improve (P = 0.033) in the NW group (med-
ian increase, 36.5 m) when compared with the LIW
(median increase, 8.0 m). Changes in pain levels and
pain threshold did not differ significantly between
groups (Table 2).
When calculated for the total group after 15 weeks of
exercise, 6MWT was significantly improved (median,
25.1; P < 0.001), Table 3. Decrease of the pain threshold
was significant (median, -9.6; P = 0.040), whereas the
decrease of pain was not (median, -5.0; P = 0.052),
Table 3.
A significant association was found between 6MWT and
the pain threshold at baseline (rs = 0.294; P = 0.040).
Change in 6MWT (Δ6MWT) was correlated with changes
in pain thresholds (ΔPT) after 15 weeks (rs = 0.339; P =
0.020) and after 30 weeks (rs = 0.407; P = 0.006).
Influence of exercise on IGF-1
No significant between-group differences were found for
changes in IGF-1 (P = 0.795) or the IGFBP-3 (P = 0.906)
occurring during the 15-week low-intensity and high-
intensity aerobic exercise, respectively.
In the NW group, IGF-1 did not significantly change
during the 15-week exercise (P = 0.300), but it decreased
at 30-week follow-up (P = 0.019). IGFBP-3 did not signifi-
cantly change during the 15-weeks (p = 0.977) or during
the 30 weeks (P = 0.426).
In the LIW group, IGF-1 did not significantly change
during the 15 weeks (median, -0.340; P = 0.148), but it
tended to decrease during the 30 weeks (P = 0.109).
IGFBP-3 did not signficantly change during the 15
weeks (P = 0.881) or 30 weeks (P = 0.796).
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Table 2 Clinical data, IGF-1, and IGFB-3 for Nordic walking group and low-intensity walking group
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-6.6 (-84.6 to 75.6)
P = 0.454









P = 0.169 P = 0.339
Pain
mm
70.5 (7 to 98) -0.5 (-40 to 25) P =
0.416
-1 (-39 to 53) P =
0.988
75 (10 to 92) -7 (-27 to 35) P =
0.067
-4 (-34 to 29) P =
0.218





36.5 (-44 to 164.5) P
< 0.001




8 (-77 to 107) P =
0.183
-2 (-62.5 to 103) P
= 0.520
P = 0.033 P = 0.049
IGF-1
ng/ml
4.3 (0 to 15.6) -0,2 (-11.4 to 28.7) P
= 0.300
-0.7 (-12.7 to 1.7) P =
0.019
3.3 (0 to 35.7) -0.3 (-31.6 to 1.9) P =
0.148
-0.1 (-31.2 to 1.4) P
= 0.109
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1,198.8) P = 0.881
242 (-1563 to
1,558.2) P = 0.796
P = 0.906 P = 0.872






















P value 30 weeks
median (range)





Pain threshold kPa 202.8 (105.9-380.5) 189.9 (112.2-305.3) -9.6 (-102.1-75.6) 0.040 194.3 (107.6-472.3) -8.8 (-165.2-108.5) 0.608
Pain
0 to 100
71 (7-98) 65.5 (3-99) -5 (-40-35) 0.052 67 (14-95) -2 (-39-53) 0.365
6MWT
m
518 (381-660) 566 (418-689 25.1 (-77-164.5) < 0.001 555 (367.5-661) 15.5 (-150.5-145) 0.009
IGF-1
ng/ml
4.2 (0-35.7) 3.0 (0-33.8) -0.2 (-31.6-28.7) 0.085 2.7 (0-10.9) -0.7 (-31.2-1.7) 0.004
IGFB3
ng/ml















When calculated for the total group, levels of either
free IGF-1 or IGFB3 did not significantly change during
the exercise period (Table 3).
Effects on IGF-1 levels and pain
Basal IGF-1 did not correlate with baseline pain (rs =
-0.026; P = 0.861). To evaluate the relation of basal IGF
to the change in pain, we did a partial correlation
between baseline IGF and final pain and adjusted for
baseline pain. We found a tendency to positive correla-
tion (r = 0.278; P = 0.059). However, this positive ten-
dency disappeared when age was accounted for (r =
0.245; P = 0.101).
Change in IGF-1 levels (ΔIGF) was associated with
ΔPT at 15 weeks (r = 0.276; P = 0.058), and the correla-
tion reached a significant level at 30-week follow-up (rs =
0.449; P = 0.005). No significant correlations were found
between ΔIGF-1 and change in rating of pain (Δpain)
when analyzed for the total group.
IGF-1 level, pain, and CSF markers
A smaller group within the study population agreed to
participate in the examination of cerebrospinal fluid at
the start of the exercise period (n = 26). Their median
age was 51 (46 to 55) years. At baseline, the number of
tender points was 14.5 (12 to 16), pain threshold was
207 (161 to 258) kPa, pain level was 70 (44 to 83), and
IGF-1 was 4.5 (2.2 to 9.3) ng/ml, implying that they did
not significantly differ from the total sample.
Fifteen individuals were able to participate in a second
examination of cerebrospinal fluid after 15 weeks. Their
median age was 51 (34 to 59) years. At baseline, tender
points for these 15 individuals was 15.0 (12 to 18), the
pain threshold was 207 (177 to 255) kPa, the pain level
was 70 (51 to 82), and IGF-1 was 4.2 (2.2 to 9.2) ng/ml,
implying that they did not significantly differ from the
total sample.
Changes in serum IGF-1 levels correlated positively with
ΔCSF NPY (rs = 0.802; P = 0.001). The correlation
between IGF-1 and ΔCSF SP tended to be significant (rs =
0.495; P = 0.072), Table 4.
Changes in pain threshold (ΔPT) were associated with
ΔCSF SP (rs = 0.600; P = 0.023), and inversely with
ΔCSF MMP-3 (rs = -0.569; P = 0.034), Table 4.
Relations between CSF markers
Baseline CSF IL-6 was positively correlated with CSF SP
(rs = 0.438; P = 0.032) and CSF MMP3 (rs = 0.409; P =
0.047). Furthermore, baseline CSF IL-6 was inversely cor-
related with CSF NGF (rs = -0.410; P = 0.042; n = 25) and
CSF NPY (rs = -0.399; P = 0.053; n = 24).
Type 1 error
Analyses of within-group analyses and between-group
analyses comprised 40 analyses (Tables 2 and 3), and
the upper level of of number of false signifcances was
1.58, which means that two significances might be false.
Analyses of correlations between IGF-1, pain, and CSF
markers (Table 4) comprised a total of 18 analyses, and
the upper level of the number of false significances was
0.79, which means that one of the significances might
be false.
Table 4 Correlation of changes in IGF-1, pain, and pain threshold, and changes in cerebrospinal markers
ΔIGF-1 (serum) ΔPain threshold ΔPain
0.495 0.539 0.075
ΔCSF SP P = 0.072 P = 0.038 P = 0.790
n = 14 n = 15 n = 15
-0.164 0.335 0.016
ΔCSF NGF P = 0.558 P = 0.204 P = 0.953
n = 15 n = 16 n = 16
0.802 0.288 0.315
ΔCSF NPY P = 0.001 P = 0.318 P = 0.273
n = 13 n = 14 n = 14
-0.165 0.225 -0.119
ΔCSF IL-6 P = 0.573 P = 0.420 P = 0.673
n = 15 n = 15 n = 15
-0.164 -0.109 0.103
ΔCSF IL-8 P = 0.558 P = 0.688 P = 0.704
n = 15 n = 16 n = 16
-0.156 -0.579 0.329
ΔCSF MMP3 P = 0.594 P = 0.024 P = 0.231
n = 14 n = 15 n = 15
Median and range (min-max) indicated. Spearmans rho(rs), two-tailed significance (P), and number of subjects (n) are presented.
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Discussion
The levels of bioactive IGF-1 and IGFBP-3 did not sig-
nificantly change between an intervention group exercis-
ing 15 weeks at moderate- to high-intensity Nordic
Walking (NW) and an active control group engaging in
low-intensity walking (LIW). Lack of changes in IGF-1
levels is in line with a previous study reporting failure to
show increase in IGF-1 in patients with FM [10]. In an
exercise study with patients with a chronic kidney disor-
der engaging in regular exercise, no change was
reported in IGF-1 [40]. Disease-specific characteristics,
such as impaired physical function and chronic pain,
may be possible reasons for the failure to increase IGF-1
and IGFBP-3 in our study.
A tendency to correlation was noted between baseline
IGF-1 and the decrease of pain in response to exercise.
However, this positive tendency disappeared when age was
accounted for, and population studies show that IGF-1
levels correlate inversely with age [41]. It might be of
interest to study levels of IGF-1 and pain during exercise
in a larger group of FM patients homogeneous in age [41].
The pain threshold was found to decrease in our study
population during the 15 weeks of exercise. This implies
that the patients exercised at a level that activated their
peripheral pain receptors [42], both in the NW and low-
intensity walking group. When calculated for the total
group, the pain scores tended to decrease after the 15-
week exercise period. Pain scoring is a global rating of
pain during the past week, thus including pain during
activities and global well-being, aspects that can be
expected to improve by both types of exercise. These
different aspects of pain may explain differences in the
two assessments. Another interesting finding was that
change in the pain threshold were found to correlate
with change in IGF-1. This indicates that serum free
IGF-1 is associated with changes in sensitivity to pain,
which must be further studied. The findings of this
study support previous studies indicating that a higher
level of IGF-1 in FM reflects better health [5,6,43,44].
Previous studies have shown that SP is increased in
cerebrospinal fluid (CSF) of patients with FM [16-18].
CSF SP levels are relatively stable over time in FM
patients; however, an increase in CSF SP over time in FM
patients has been associated with small increases in pain
or tenderness [16]. In our material, change in CSF SP
was positively associated with changes in pain threshold.
The change of CSF SP levels during aerobic exercise has,
to our best knowledge, not been previously studied in
patients with FM, but it has previously been found that
SP is involved mainly in initiation rather than mainte-
nance of chronic pain [45]. Regular exercise has shown
beneficial effects on brain function [46]. Exercise effects
on brain function, including mobilization of BDNF, are
dependent on IGF-1 and IGF-1 uptake into the brain
[47]. A possible interpretation of our data is that exer-
cise-induced peaks of IGF-1 combined with high chronic
levels of CSF SP may lead to long-term adaptation to tol-
erate physical strain. Thus, IGF-1 may promote resilience
to pain in the CNS. In experimental diabetic neuropathy,
treatment with IGF-1 reversed neuronal hyperactivity in
the spinal cord and in the periaqueductal gray matter
and prevented behavioral signs of pain [48]. In RA and
AS patients, early response to exercise led to increased
IGF-1 levels and reduced pain [49]. Furthermore, daily
growth hormone treatment in FM patients led to
increased IGF-1 and reduced pain levels [50]. Future stu-
dies are needed to determine short-term changes of the
IGF-1 in relation to exercise in patients with FM.
We studied MMP3 in CSF for its potential role in
structural reorganization and inflammation and found
that change in CSF MMP-3 correlated negatively with
change in pain threshold, which supports the notion
that MMP3 is modulated during exercise [33,51]. The
correlation between CSF MMP-3 and CSF IL-6 at base-
line in our material may represent MMP-3 release
induced by inflammatory cytokines [34,52,53], or stimu-
lation of local inflammatory cytokine production by
MMP-3 [54]. This study is, to our best knowledge, the
first publication reporting changes in these substances
during a prospective exercise period.
Conclusions
Levels of free IGF-1 and IGFB3 in serum did not change
during 15 weeks of aerobic exercise in patients with FM.
Baseline IGF-1 was associated with a decrease of pain in
response to exercise, but the tendency disappeared
when adjusted for age.
Changes in levels of IGF-1 correlated positively with
changes in SP and NPY in CSF and with changes in
pain threshold. It appears that higher level of IGF-1
indicates less pain during exercise in FM, which must
be further studied.
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